title: Safety of Human Hepatoma Cell-Line Constructing Bioartificial Liver Supporting System Treating Patients with Liver Failure.
abstract: OBJECTIVE
  To observe the clinical safety of bioartificial liver supporting system constructed by human hepatoma cell line.
  
  
  METHODS
  Seventeen patients with liver failure were treated with C3A-cell-constructed bioartificial liver supporting system, contrasting the difference of biochemical results and imaging data with 9 patients treated with non-bioartificial liver during 5-year treatment.
  
  
  RESULTS
  11 cases of Treatment Group survived at 3 months' follow-up, among whom 2 cases underwent hepatic transplantation. 9 cases without hepatic transplantation survived in 5-year follow-up, and 1 of them was found to occur focal liver lesion at the 5th years, and had hepatic lobectomy. Pathological prompt: hepatocellular carcinoma with moderate differentiation. Totally 4 patients in Control Group survived after 3 months' follow-up, including 1 patient of hepatic transplantation. All the 3 patients without hepatic transplantation survived the last 5-year follow-up, with basically normal biochemical indicators and no focal liver lesion were found by imaging examination.
  
  
  CONCLUSIONS
  It was safe to use bioartificial liver constructed by tumor cell line C3A to treat liver failure.
authors.forename: Shaoli
authors.initials: S
authors.lastname: You
authors.forename: Bing
authors.initials: B
authors.lastname: Zhu
authors.forename: Hongling
authors.initials: H
authors.lastname: Liu
authors.forename: Yihui
authors.initials: Y
authors.lastname: Rong
authors.forename: Wanmei
authors.initials: W
authors.lastname: Liu
authors.forename: Hong
authors.initials: H
authors.lastname: Zang
authors.forename: Aimin
authors.initials: A
authors.lastname: Zhang
authors.forename: Zhihong
authors.initials: Z
authors.lastname: Wan
authors.forename: Shaojie
authors.initials: S
authors.lastname: Xin
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000378:metabolism*; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D017093:Liver Failure / Q000175:diagnosis / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000378:metabolism*; D016031:Liver Transplantation; D019164:Liver, Artificial / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D013997:Time Factors; D023822:Tissue Engineering / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers